RU2016141622A - Нетоксичный адъювантный состав, содержащий композицию содержащей монофосфорил-липид а (mpla) липосомы и сапонин - Google Patents

Нетоксичный адъювантный состав, содержащий композицию содержащей монофосфорил-липид а (mpla) липосомы и сапонин Download PDF

Info

Publication number
RU2016141622A
RU2016141622A RU2016141622A RU2016141622A RU2016141622A RU 2016141622 A RU2016141622 A RU 2016141622A RU 2016141622 A RU2016141622 A RU 2016141622A RU 2016141622 A RU2016141622 A RU 2016141622A RU 2016141622 A RU2016141622 A RU 2016141622A
Authority
RU
Russia
Prior art keywords
less
approximately
mol
composition
liposome
Prior art date
Application number
RU2016141622A
Other languages
English (en)
Russian (ru)
Other versions
RU2016141622A3 (enExample
Inventor
Карл Р. АЛВИНГ
Золтан БЭК
Original Assignee
Зэ Гавермент Оф Зэ Юнайтед Стэйтс Оф Америка Эс Репрезентед Бай Зэ Секретари Оф Зэ Арми
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зэ Гавермент Оф Зэ Юнайтед Стэйтс Оф Америка Эс Репрезентед Бай Зэ Секретари Оф Зэ Арми filed Critical Зэ Гавермент Оф Зэ Юнайтед Стэйтс Оф Америка Эс Репрезентед Бай Зэ Секретари Оф Зэ Арми
Publication of RU2016141622A publication Critical patent/RU2016141622A/ru
Publication of RU2016141622A3 publication Critical patent/RU2016141622A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2016141622A 2014-03-25 2015-03-25 Нетоксичный адъювантный состав, содержащий композицию содержащей монофосфорил-липид а (mpla) липосомы и сапонин RU2016141622A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461970118P 2014-03-25 2014-03-25
US61/970,118 2014-03-25
PCT/US2015/022461 WO2015148648A1 (en) 2014-03-25 2015-03-25 Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin

Publications (2)

Publication Number Publication Date
RU2016141622A true RU2016141622A (ru) 2018-04-25
RU2016141622A3 RU2016141622A3 (enExample) 2018-10-26

Family

ID=52829375

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016141622A RU2016141622A (ru) 2014-03-25 2015-03-25 Нетоксичный адъювантный состав, содержащий композицию содержащей монофосфорил-липид а (mpla) липосомы и сапонин

Country Status (11)

Country Link
US (1) US10434167B2 (enExample)
EP (1) EP3122380B1 (enExample)
JP (1) JP6608422B2 (enExample)
KR (1) KR102242875B1 (enExample)
CN (1) CN107124869B (enExample)
AU (1) AU2015236106A1 (enExample)
CA (1) CA2943190A1 (enExample)
MX (1) MX2016012168A (enExample)
RU (1) RU2016141622A (enExample)
SG (2) SG10201808315UA (enExample)
WO (1) WO2015148648A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109152361A (zh) * 2016-03-09 2019-01-04 技术研究及发展基金有限公司 脂质体制剂及在农业中使用该脂质体制剂的方法
JP6661454B2 (ja) * 2016-04-21 2020-03-11 株式会社東海理化電機製作所 表示装置、表示板の製造方法
WO2018200645A1 (en) * 2017-04-25 2018-11-01 Adjuvance Technologies, Inc. Triterpene saponin analogues
EP3615005B1 (en) * 2017-04-28 2025-07-30 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Compositions and methods for vaccine delivery
CN107669692B (zh) * 2017-09-07 2020-09-29 中国人民解放军第二军医大学 Mpla在制备电离辐射致肠道损伤防治药物中的应用
CA3078223A1 (en) * 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
WO2020243166A1 (en) * 2019-05-28 2020-12-03 The Regents Of The University Of California Th1-polarizing adjuvants for enhancing immunogenicity of hiv antigens
CN110613844B (zh) * 2019-10-23 2024-02-27 中国医学科学院生物医学工程研究所 一种迷你联合佐剂纳米颗粒及其制备方法和应用
AU2020407871A1 (en) 2019-12-20 2022-06-30 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof
EP3892296A1 (en) * 2020-04-07 2021-10-13 InnoMedica Holding AG Immunogenic composition comprising an antigenic moiety and a liposomal formulation, method of producing the composition, the composition for use as a medicament, in particular for use as a vaccine
WO2022003443A1 (ko) * 2020-06-30 2022-01-06 아이진 주식회사 양이온성 리포좀을 포함하는 사포닌의 용혈 억제용 조성물
GB2600468A (en) * 2020-10-30 2022-05-04 Excivion Ltd Adjuvant composition
CN112546233A (zh) * 2020-12-25 2021-03-26 常州大学 一种负载水不溶性免疫调节分子的透明质酸复合材料及其制备方法
CN114366810B (zh) * 2022-02-15 2024-11-22 中国人民解放军陆军军医大学 一种可高效诱导体液和细胞免疫的天然微生物和植物来源复合双佐剂及其制备方法和应用
US20250177516A1 (en) 2022-03-14 2025-06-05 Pfizer Inc. Methods for producing an adjuvant
JP2025532724A (ja) 2022-09-29 2025-10-03 ファイザー・インク Ｒｓｖ ｆタンパク質三量体を含む免疫原性組成物
IL321069A (en) 2022-12-01 2025-07-01 Pfizer Pneumococcal conjugate vaccine preparations
IL320955A (en) * 2022-12-13 2025-07-01 Pfizer Immunogenic compounds and methods for generating an immune response against CLOSTRIDIIOIDES (CLOSTRIDIUM) DIFCILE
WO2025057058A1 (en) * 2023-09-13 2025-03-20 Pfizer Inc. Methods for producing an adjuvant
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
WO2025163460A2 (en) 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
CN117771361B (zh) * 2024-02-27 2024-06-07 天津中逸安健生物科技有限公司 一种聚肌苷酸-聚胞苷酸复合物的脂质纳米佐剂及其制备方法与应用
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4302459A (en) 1980-03-19 1981-11-24 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in leishmaniasis chemotherapy with 8-aminoquinoline derivatives
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4684479A (en) 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
CN1093255A (zh) * 1986-06-17 1994-10-12 恩特雷麦德有限公司 抗甾醇疫苗
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US5888519A (en) 1988-06-02 1999-03-30 The United States Of America As Represented By The Secretary Of The Army Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections
US5215680A (en) 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
EP0761231B1 (en) * 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
WO1994014454A1 (en) 1992-12-29 1994-07-07 Entremed, Inc. Vaccines against sterols
GB9320668D0 (en) * 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
US6846489B1 (en) * 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO1998007409A1 (en) 1996-08-23 1998-02-26 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
EP0932390A1 (en) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
NZ336538A (en) 1996-10-15 2001-11-30 Liposome Co Inc N-acyl phosphatidylethanolamine-mediated liposomal drug delivery
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CN101711278B (zh) * 2007-03-01 2013-08-14 美国天主教大学 与基质结合的t4噬菌体
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
WO2012088414A1 (en) * 2010-12-23 2012-06-28 Ludwig Institute For Cancer Research Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof

Also Published As

Publication number Publication date
EP3122380B1 (en) 2025-03-19
KR20170007242A (ko) 2017-01-18
CN107124869B (zh) 2022-04-01
JP2017515889A (ja) 2017-06-15
US20170182152A1 (en) 2017-06-29
SG11201607396WA (en) 2016-10-28
CA2943190A1 (en) 2015-10-01
KR102242875B1 (ko) 2021-04-20
MX2016012168A (es) 2017-04-25
SG10201808315UA (en) 2018-10-30
EP3122380A1 (en) 2017-02-01
CN107124869A (zh) 2017-09-01
AU2015236106A1 (en) 2016-10-20
RU2016141622A3 (enExample) 2018-10-26
JP6608422B2 (ja) 2019-11-20
US10434167B2 (en) 2019-10-08
WO2015148648A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
RU2016141622A (ru) Нетоксичный адъювантный состав, содержащий композицию содержащей монофосфорил-липид а (mpla) липосомы и сапонин
JP2017515889A5 (enExample)
JP6194248B2 (ja) 非ステロイド性抗炎症薬の徐放性処方物
KR102483033B1 (ko) 페길화된 리포솜 및 이의 용도
JP2020533340A5 (enExample)
AU2013299453B2 (en) Neuroprotective liposome compositions and methods for treatment of stroke
WO2010041255A2 (en) Liposomal systems comprising sphingomyelin
JP2005525992A (ja) 生物学的物質を充填した小胞の調製法およびそれらの様々な使用
TWI896950B (zh) 佐劑之製造方法
BE1024094B1 (fr) Vaccin
JP2007511505A (ja) リポソームにおける薬剤充填法
JP7136777B2 (ja) 新規プロセス
CN117979970A (zh) 布比卡因多囊脂质体制剂及其用途
US20120207821A1 (en) Liposomal formulation and use thereof
RU2476216C1 (ru) Липосомальная композиция
JP2017511802A (ja) 免疫原リポソーム製剤
Nardo et al. In vivo assessment of triazine lipid nanoparticles as transfection agents for plasmid DNA
JPH09501168A (ja) 生物構造体、生体ポリマー及び／又はオリゴマーを充填した小胞の調製方法
JP2001026544A (ja) 脂溶性抗腫瘍薬のリポソーム製剤
JP6026339B2 (ja) 経皮吸収剤用のリポソーム担体
CN118900684A (zh) 制备佐剂的方法
WO2022236370A1 (en) Immunogenic composition
RU2021132189A (ru) Фармацевтическая композиция слабокислотного лекарственного средства и способы применения

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190513